• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

整合血清药物化学、16S rRNA测序和代谢组学以揭示茵栀黄颗粒抗非酒精性脂肪性肝病的物质基础和作用机制。

Integrated serum pharmacochemistry, 16S rRNA sequencing and metabolomics to reveal the material basis and mechanism of Yinzhihuang granule against non-alcoholic fatty liver disease.

作者信息

Tan Yingying, Huang Zhihong, Liu Yingying, Li Xiaojiaoyang, Stalin Antony, Fan Xiaotian, Wu Zhishan, Wu Chao, Lu Shan, Zhang Fanqin, Chen Meilin, Huang Jiaqi, Cheng Guoliang, Li Bing, Guo Siyu, Yang Yu, Zhang Shuofeng, Wu Jiarui

机构信息

School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.

School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, China.

出版信息

J Ethnopharmacol. 2023 Jun 28;310:116418. doi: 10.1016/j.jep.2023.116418. Epub 2023 Mar 27.

DOI:10.1016/j.jep.2023.116418
PMID:36990301
Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Yinzhihuang granule (YZHG) has liver protective effect and can be used for clinical treatment of non-alcoholic fatty liver disease (NAFLD), but its material basis and mechanism need to be further clarified.

AIM OF THE STUDY

This study aims to reveal the material basis and mechanism of YZHG treating NAFLD.

MATERIALS AND METHODS

Serum pharmacochemistry were employed to identify the components from YZHG. The potential targets of YZHG against NAFLD were predicted by system biology and then preliminarily verified by molecular docking. Furthermore, the functional mechanism of YZHG in NAFLD mice was elucidated by 16S rRNA sequencing and untargeted metabolomics.

RESULTS

From YZHG, 52 compounds were identified, of which 42 were absorbed into the blood. Network pharmacology and molecular docking showed that YZHG treats NAFLD with multi-components and multi-targets. YZHG can improve the levels of blood lipids, liver enzymes, lipopolysaccharide (LPS), and inflammatory factors in NAFLD mice. YZHG can also significantly improve the diversity and richness of intestinal flora and regulate glycerophospholipid and sphingolipid metabolism. Moreover, Western Blot experiment showed that YZHG can regulate liver lipid metabolism and enhance intestinal barrier function.

CONCLUSIONS

YZHG may treat NAFLD by improving the disruption of intestinal flora and enhancing the intestinal barrier. This will reduce the invasion of LPS into the liver subsequently regulate liver lipid metabolism and reduce liver inflammation.

摘要

民族药理学相关性

茵栀黄颗粒(YZHG)具有肝脏保护作用,可用于临床治疗非酒精性脂肪性肝病(NAFLD),但其物质基础和作用机制尚需进一步阐明。

研究目的

本研究旨在揭示茵栀黄颗粒治疗非酒精性脂肪性肝病的物质基础和作用机制。

材料与方法

采用血清药物化学方法鉴定茵栀黄颗粒中的成分。通过系统生物学预测茵栀黄颗粒抗非酒精性脂肪性肝病的潜在靶点,然后通过分子对接进行初步验证。此外,通过16S rRNA测序和非靶向代谢组学阐明茵栀黄颗粒在非酒精性脂肪性肝病小鼠中的作用机制。

结果

从茵栀黄颗粒中鉴定出52种化合物,其中42种被吸收入血。网络药理学和分子对接表明,茵栀黄颗粒通过多成分、多靶点治疗非酒精性脂肪性肝病。茵栀黄颗粒可改善非酒精性脂肪性肝病小鼠的血脂、肝酶、脂多糖(LPS)和炎症因子水平。茵栀黄颗粒还可显著提高肠道菌群的多样性和丰富度,调节甘油磷脂和鞘脂代谢。此外,蛋白质免疫印迹实验表明,茵栀黄颗粒可调节肝脏脂质代谢,增强肠道屏障功能。

结论

茵栀黄颗粒可能通过改善肠道菌群紊乱和增强肠道屏障来治疗非酒精性脂肪性肝病。这将减少LPS侵入肝脏,随后调节肝脏脂质代谢,减轻肝脏炎症。

相似文献

1
Integrated serum pharmacochemistry, 16S rRNA sequencing and metabolomics to reveal the material basis and mechanism of Yinzhihuang granule against non-alcoholic fatty liver disease.整合血清药物化学、16S rRNA测序和代谢组学以揭示茵栀黄颗粒抗非酒精性脂肪性肝病的物质基础和作用机制。
J Ethnopharmacol. 2023 Jun 28;310:116418. doi: 10.1016/j.jep.2023.116418. Epub 2023 Mar 27.
2
Exploring the effect of Yinzhihuang granules on alcoholic liver disease based on pharmacodynamics, network pharmacology and molecular docking.基于药效学、网络药理学和分子对接探索茵栀黄颗粒对酒精性肝病的作用
Chin Med. 2023 May 11;18(1):52. doi: 10.1186/s13020-023-00759-z.
3
Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: A 16S rRNA and non-targeted metabolomics analyses.糖肾方通过靶向肠道微生物群治疗 HFD 小鼠非酒精性脂肪肝病:16S rRNA 和非靶向代谢组学分析。
Biomed Pharmacother. 2024 Apr;173:116405. doi: 10.1016/j.biopha.2024.116405. Epub 2024 Mar 14.
4
Mechanism of Xiaoyao San in treating non-alcoholic fatty liver disease with liver depression and spleen deficiency: based on bioinformatics, metabolomics and experiments.逍遥散治疗肝郁脾虚型非酒精性脂肪性肝病的作用机制:基于生物信息学、代谢组学和实验研究。
J Biomol Struct Dyn. 2024 Jul;42(10):5128-5146. doi: 10.1080/07391102.2023.2231544. Epub 2023 Jul 13.
5
Corrigendum to "Integrated serum pharmacochemistry, 16S rRNA sequencing and metabolomics to reveal the material basis and mechanism of Yinzhihuang granule against non-alcoholic fatty liver disease" [J. Ethnopharmacol. 310 (2023) 116418].《整合血清药物化学、16S rRNA测序和代谢组学揭示茵栀黄颗粒抗非酒精性脂肪性肝病的物质基础和作用机制》的勘误 [《民族药理学杂志》310 (2023) 116418]
J Ethnopharmacol. 2024 Jan 10;318(Pt A):116822. doi: 10.1016/j.jep.2023.116822. Epub 2023 Jun 28.
6
Prediction and verification of the active ingredients and potential targets of Erhuang Quzhi Granules on non-alcoholic fatty liver disease based on network pharmacology.基于网络药理学的二黄祛脂颗粒治疗非酒精性脂肪性肝病活性成分及潜在靶点的预测与验证
J Ethnopharmacol. 2023 Jul 15;311:116435. doi: 10.1016/j.jep.2023.116435. Epub 2023 Apr 5.
7
Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function.五味子甲素通过恢复肠道屏障功能来缓解非酒精性脂肪性肝病。
Front Cell Infect Microbiol. 2022 Sep 5;12:855008. doi: 10.3389/fcimb.2022.855008. eCollection 2022.
8
Terminalia bellirica ethanol extract ameliorates nonalcoholic fatty liver disease in mice by amending the intestinal microbiota and faecal metabolites.毗黎勒乙醇提取物通过改善肠道微生物群和粪便代谢产物来改善小鼠非酒精性脂肪性肝病。
J Ethnopharmacol. 2023 Apr 6;305:116082. doi: 10.1016/j.jep.2022.116082. Epub 2022 Dec 27.
9
The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial.健脾疏肝方通过调节肠道菌群治疗非酒精性脂肪性肝病的临床试验。
Front Endocrinol (Lausanne). 2023 Jan 19;13:1107071. doi: 10.3389/fendo.2022.1107071. eCollection 2022.
10
Molecular mechanism of Ginkgo biloba in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease based on network pharmacology, molecular docking, and experimental evaluations.基于网络药理学、分子对接和实验评估的银杏叶治疗2型糖尿病合并非酒精性脂肪性肝病的分子机制
J Food Biochem. 2022 Dec;46(12):e14419. doi: 10.1111/jfbc.14419. Epub 2022 Sep 19.

引用本文的文献

1
Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease.靶向肠道微生物群与脂质代谢:天然产物治疗非酒精性脂肪性肝病的潜在机制
Front Pharmacol. 2025 Jun 9;16:1610498. doi: 10.3389/fphar.2025.1610498. eCollection 2025.
2
Unraveling the molecular mechanisms of Fufangduzhong formula in alleviating high-fat diet-induced non-alcoholic fatty liver disease in mice.解析复方杜仲方缓解高脂饮食诱导的小鼠非酒精性脂肪性肝病的分子机制。
Front Pharmacol. 2025 Mar 12;16:1542143. doi: 10.3389/fphar.2025.1542143. eCollection 2025.
3
Study on biotransformation and absorption of genistin based on fecal microbiota and Caco-2 cell.
基于粪便微生物群和Caco-2细胞的染料木苷生物转化与吸收研究
Front Pharmacol. 2024 Oct 9;15:1437020. doi: 10.3389/fphar.2024.1437020. eCollection 2024.
4
Effect of Bile Acids Supplementation in Fatty Liver Hemorrhagic Syndrome, Production Performance, Physiological and Quality Characteristics of Laying Hen Eggs.补充胆汁酸对蛋鸡脂肪肝出血综合征、生产性能、生理及蛋品质特性的影响
Animals (Basel). 2024 Jun 28;14(13):1910. doi: 10.3390/ani14131910.
5
Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review.基于网络药理学的中医治疗非酒精性脂肪性肝病研究进展
Front Pharmacol. 2024 Apr 17;15:1381712. doi: 10.3389/fphar.2024.1381712. eCollection 2024.
6
Liangxue-Qushi-Zhiyang Decoction Ameliorates DNCB-Induced Atopic Dermatitis in Mice through the MAPK Signaling Pathway Based on Network Pharmacology.基于网络药理学,凉血祛湿止痒汤通过MAPK信号通路改善二硝基氯苯诱导的小鼠特应性皮炎
ACS Omega. 2024 Apr 10;9(16):17931-17944. doi: 10.1021/acsomega.3c09218. eCollection 2024 Apr 23.
7
Lactiplantibacillus plantarum FRT4 attenuates high-energy low-protein diet-induced fatty liver hemorrhage syndrome in laying hens through regulating gut-liver axis.植物乳杆菌FRT4通过调节肠-肝轴减轻高能低蛋白饮食诱导的蛋鸡脂肪肝出血综合征。
J Anim Sci Biotechnol. 2024 Feb 21;15(1):31. doi: 10.1186/s40104-023-00982-6.